Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
Jun GongAlain C MitaZihan WeiHeather H ChengEdith P MitchellJohn J WrightSusan Percy IvyVictoria WangRobert C GrayLisa Meier McShaneLawrence V RubinsteinDavid R PattonP Mickey WilliamsStanley R HamiltonJames V TricoliBarbara A ConleyCarlos L ArteagaLyndsay N HarrisPeter J O'DwyerAlice P ChenKeith T FlahertyPublished in: JCO precision oncology (2024)
This study met its primary end point in patients with several pretreated solid tumor types harboring FGFR1-3 mutations or fusions. These findings support advancement of erdafitinib for patients with fibroblast growth factor receptor-altered tumors outside of currently approved indications in a potentially tumor-agnostic manner.